NEW YORK (GenomeWeb News) – Cancer Genetics and Roche Servicios today announced the expansion of an agreement covering molecular diagnostic testing in Central America and the Caribbean.
Roche Servicios is an affiliate of Roche.
Under the three-year contract, Cancer Genetics will use Roche's cobas platform and will be the exclusive provider of molecular diagnostic cancer testing for Roche Servicios in Central America and the Caribbean. The deal covers several diseases, including lung cancer, breast cancer, and lymphoma, and will begin by focusing on cobas-based testing with the epidermal growth factor receptor mutation test approved by the US Food and Drug Administration.
Upon mutual agreement by Cancer Genetics and Roche, the deal may also be expanded to include other cancers as well as other geographies, they said.
Financial and other terms were not disclosed.
Cancer Genetics and Roche Servicios originally forged their deal in the summer of 2012 to identify patients in Central America and the Caribbean who may best respond to oncology drugs from Roche and its Genentech business unit.
"Our proprietary testing solutions coupled with state-of-the-art molecular testing enables Roche Servicios to deliver personalized cancer treatment for their patients throughout the region, bringing state-of-the-art biomarker-based cancer testing into the community setting where it will have the greatest impact," Cancer Genetics CEO Panna Sharma said in a statement.